Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
NCI awards Fred Hutch $3.5M to create a colorectal cancer risk calculator based on data from multiethnic populations.
SU2C Health Equity Initiative aims to reduce racial and ethnic disparities in cancer research and improve outcomes for minority populations.
The study raises concerns about the effectiveness of cancer drugs, as genetic differences may affect how someone responds to a drug.
Collaboration with Lazarex Cancer Foundation tests new ways to erase cost barriers in major public health issue.
Overall, few people actually sign up for and participate in trials, and those who do participate don’t always represent the U.S. population.
NCI is expanding eligibility criteria for its cancer clinical trials in the hope that more people will enroll.
Less than 5 percent of Black patients were involved in trials for 24 out of 31 cancer drugs approved since 2015.
Forty-five years since its launch, SEER can become an invaluable resource for performing and informing clinical and even basic research.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.